FELDAN THERAPEUTICS PARTNERS WITH TRANSBIOTECH ON NSERC-FUNDED PROJECT TO ACCELERATE DEVELOPMENT OF INNOVATIVE INTRALESIONAL TREATMENTS

Quebec City, QC, March 12, 2026 – Feldan Therapeutics (“Feldan”), a clinical-stage biotech company specializing in the development of therapies based on intracellular delivery, today announced, in partnership with TransBIOTech, the receipt of a CA$450,000 grant. This Applied Research and Development (ARD) funding was awarded through the College and Community Innovation (CCI) program, administered by the Natural Sciences and Engineering Research Council of Canada (NSERC), in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and the Canadian Institutes of Health Research (CIHR).

The non-dilutive grant will fund, over three years, the development of novel intralesional therapeutic approaches by Feldan to target tumor lesions, with TransBIOTech conducting in vivo experiments as part of the collaboration.

Through this initiative, Feldan continues to capitalize on its proprietary intracellular delivery platform, the Feldan Shuttle, enabling the development of diverse therapies, including targeted intralesional approaches for tumor and fibrotic lesions. By progressing Shuttle-enabled therapeutic candidates, the company aims to deliver life-changing treatments for patients while reinforcing Canada’s position in cutting-edge biomedical research. Collaborating with TransBIOTech further strengthens Feldan’s ability to translate its technology into tangible clinical solutions.

This initiative builds on the company’s expertise and ongoing development efforts, including its current Phase 1/2a clinical trial evaluating FLD-103, a non-surgical treatment for basal cell carcinoma, the most common form of skin cancer. At Feldan, the work will be led by Nancy Messier, VP – Drug Discovery, and her team.

“Our team is proud to secure this support from NSERC and thanks TransBIOTech for its partnership and contribution to advancing our efforts,” said Dr. François-Thomas Michaud, CEO of Feldan Therapeutics. “This award highlights the potential of our intracellular delivery platform and facilitates the expansion of our pipeline of therapeutic candidates. By leveraging our expertise in intralesional approaches, we continue to advance differentiated treatment strategies aimed at improving outcomes for patients.”

TransBIOTech is a Canadian research centre supporting biotech companies in the development of innovative therapeutics through flexible, high-quality preclinical research services. TransBIOTech possesses the expertise and infrastructure required to successfully conduct all aspects of this research project. The work will be co-led by Dr. Frédéric Couture, Principal Investigator and Head of the Pharmaceutical Sciences Department at TransBIOTech, and Dr. Carole-Ann Huppé, Principal Investigator specializing in Immunology. The project will be supported by TransBIOTech’s highly skilled technical teams within its preclinical animal care facility and biology–immunology laboratories, ensuring the rigorous execution of the experimentations. Together, this multidisciplinary expertise enables TransBIOTech to generate robust preclinical data and support partners in advancing promising therapies toward clinical development.

“Supporting Feldan Therapeutics in advancing their innovative therapies through the Feldan Shuttle for nearly a decade has been incredibly rewarding,” said Dr. Frédéric Couture, Principal Investigator and Head of Preclinical Pharmacology at TransBIOTech. “Our team is proud to support Feldan in this new project, which will further strengthen our expertise in evaluating novel delivery platforms against solid tumors while generating key data to advance this promising therapeutic approach.”

As Canada’s primary federal agency for funding natural sciences and engineering research, NSERC supports collaborations that drive innovation and economic growth. Programs such as CCI enhance research capacity and help accelerate the development of new treatments addressing unmet medical needs.

About Feldan
Feldan is a clinical-stage biotech company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan has developed the Feldan Shuttle, a proprietary peptide-based technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASO) to cells. This technology unlocks the potential for a new generation of therapeutics by giving access to intracellular targets that are otherwise beyond reach.

Feldan’s pipeline focuses on diseases affecting the skin and lungs. The company is conducting a Phase 1/2a clinical trial of FLD-103, a non-surgical treatment for basal cell carcinoma (BCC). To offer additional life-changing therapeutics to patients, Feldan is advancing FLD-201, an inhaled therapy for mucus-driven diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development. These programs leverage Feldan’s Shuttle technology, which is being further developed for broader applications.
For more information: www.feldan.com

About TransBIOTech
TransBIOTech, a College Center for Technology Transfer (CCTT) affiliated with Cégep de Lévis, QC, Canada, is a non-profit organization specializing in biotechnology. Since 1999, TransBIOTech has been offering expert support in drug development, providing services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics, and toxicology. TransBIOTech researchers use their expertise and advanced methodologies to evaluate the mechanism of action, efficacy, and safety of therapeutic candidates at various stages of preclinical development.
For more information: www.transbio.tech

Contacts:
Feldan
Stéphanie Levesque
Director – Corporate Governance & Communications
slevesque@feldan.com

TransBIOTech
Delphine Davan
Head, Partnership & Business Development
delphine.davan@tbt.qc.ca
418 833-8876